82 related articles for article (PubMed ID: 38538744)
21. BCL2 and MCL1 inhibitors for hematologic malignancies.
Roberts AW; Wei AH; Huang DCS
Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
[TBL] [Abstract][Full Text] [Related]
22. Targeting MCL-1 in cancer: current status and perspectives.
Wang H; Guo M; Wei H; Chen Y
J Hematol Oncol; 2021 Apr; 14(1):67. PubMed ID: 33883020
[TBL] [Abstract][Full Text] [Related]
23. The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.
Lemos C; Schulze VK; Baumgart SJ; Nevedomskaya E; Heinrich T; Lefranc J; Bader B; Christ CD; Briem H; Kuhnke LP; Holton SJ; Bömer U; Lienau P; von Nussbaum F; Nising CF; Bauser M; Hägebarth A; Mumberg D; Haendler B
Cell Oncol (Dordr); 2021 Jun; 44(3):581-594. PubMed ID: 33492659
[TBL] [Abstract][Full Text] [Related]
24. Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor.
Szlavik Z; Csekei M; Paczal A; Szabo ZB; Sipos S; Radics G; Proszenyak A; Balint B; Murray J; Davidson J; Chen I; Dokurno P; Surgenor AE; Daniels ZM; Hubbard RE; Le Toumelin-Braizat G; Claperon A; Lysiak-Auvity G; Girard AM; Bruno A; Chanrion M; Colland F; Maragno AL; Demarles D; Geneste O; Kotschy A
J Med Chem; 2020 Nov; 63(22):13762-13795. PubMed ID: 33146521
[TBL] [Abstract][Full Text] [Related]
25. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
[TBL] [Abstract][Full Text] [Related]
26. Cell Death in the Origin and Treatment of Cancer.
Strasser A; Vaux DL
Mol Cell; 2020 Jun; 78(6):1045-1054. PubMed ID: 32516599
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate.
Hu L; Chen M; Chen X; Zhao C; Fang Z; Wang H; Dai H
Cell Death Dis; 2020 Apr; 11(4):281. PubMed ID: 32332857
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
[TBL] [Abstract][Full Text] [Related]
29. Energy-stress-mediated AMPK activation inhibits ferroptosis.
Lee H; Zandkarimi F; Zhang Y; Meena JK; Kim J; Zhuang L; Tyagi S; Ma L; Westbrook TF; Steinberg GR; Nakada D; Stockwell BR; Gan B
Nat Cell Biol; 2020 Feb; 22(2):225-234. PubMed ID: 32029897
[TBL] [Abstract][Full Text] [Related]
30. Induction of apoptosis in hematological cancer cells by dorsomorphin correlates with BAD upregulation.
Liu Z; Zhang G; Huang S; Cheng J; Deng T; Lu X; Adeshakin FO; Chen Q; Wan X
Biochem Biophys Res Commun; 2020 Feb; 522(3):704-708. PubMed ID: 31787232
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
Guièze R; Liu VM; Rosebrock D; Jourdain AA; Hernández-Sánchez M; Martinez Zurita A; Sun J; Ten Hacken E; Baranowski K; Thompson PA; Heo JM; Cartun Z; Aygün O; Iorgulescu JB; Zhang W; Notarangelo G; Livitz D; Li S; Davids MS; Biran A; Fernandes SM; Brown JR; Lako A; Ciantra ZB; Lawlor MA; Keskin DB; Udeshi ND; Wierda WG; Livak KJ; Letai AG; Neuberg D; Harper JW; Carr SA; Piccioni F; Ott CJ; Leshchiner I; Johannessen CM; Doench J; Mootha VK; Getz G; Wu CJ
Cancer Cell; 2019 Oct; 36(4):369-384.e13. PubMed ID: 31543463
[TBL] [Abstract][Full Text] [Related]
32. Dorsomorphin induces cancer cell apoptosis and sensitizes cancer cells to HSP90 and proteasome inhibitors by reducing nuclear heat shock factor 1 levels.
Li N; Wang T; Li Z; Ye X; Deng B; Zhuo S; Yao P; Yang M; Mei H; Chen X; Zhu T; Chen S; Wang H; Wang J; Le Y
Cancer Biol Med; 2019 May; 16(2):220-233. PubMed ID: 31516744
[TBL] [Abstract][Full Text] [Related]
33. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.
Singh R; Letai A; Sarosiek K
Nat Rev Mol Cell Biol; 2019 Mar; 20(3):175-193. PubMed ID: 30655609
[TBL] [Abstract][Full Text] [Related]
34. Humanized
Brennan MS; Chang C; Tai L; Lessene G; Strasser A; Dewson G; Kelly GL; Herold MJ
Blood; 2018 Oct; 132(15):1573-1583. PubMed ID: 30139826
[TBL] [Abstract][Full Text] [Related]
35. AMPK promotes survival of c-Myc-positive melanoma cells by suppressing oxidative stress.
Kfoury A; Armaro M; Collodet C; Sordet-Dessimoz J; Giner MP; Christen S; Moco S; Leleu M; de Leval L; Koch U; Trumpp A; Sakamoto K; Beermann F; Radtke F
EMBO J; 2018 Mar; 37(5):. PubMed ID: 29440228
[TBL] [Abstract][Full Text] [Related]
36. Measurement of BH3-only protein tolerance.
Dai H; Ding H; Peterson KL; Meng XW; Schneider PA; Knorr KLB; Kaufmann SH
Cell Death Differ; 2018 Feb; 25(2):282-293. PubMed ID: 29053140
[TBL] [Abstract][Full Text] [Related]
37. Targeting BCL-2-like Proteins to Kill Cancer Cells.
Cory S; Roberts AW; Colman PM; Adams JM
Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
[TBL] [Abstract][Full Text] [Related]
38. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
Kotschy A; Szlavik Z; Murray J; Davidson J; Maragno AL; Le Toumelin-Braizat G; Chanrion M; Kelly GL; Gong JN; Moujalled DM; Bruno A; Csekei M; Paczal A; Szabo ZB; Sipos S; Radics G; Proszenyak A; Balint B; Ondi L; Blasko G; Robertson A; Surgenor A; Dokurno P; Chen I; Matassova N; Smith J; Pedder C; Graham C; Studeny A; Lysiak-Auvity G; Girard AM; Gravé F; Segal D; Riffkin CD; Pomilio G; Galbraith LC; Aubrey BJ; Brennan MS; Herold MJ; Chang C; Guasconi G; Cauquil N; Melchiore F; Guigal-Stephan N; Lockhart B; Colland F; Hickman JA; Roberts AW; Huang DC; Wei AH; Strasser A; Lessene G; Geneste O
Nature; 2016 Oct; 538(7626):477-482. PubMed ID: 27760111
[TBL] [Abstract][Full Text] [Related]
39. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
40. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
